All In Biotech

Drug Trial Radar · NCT06126835

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

Ozanimod Pregnancy Safety Study in Pregnant Women With Ulcerative Colitis and Their Offspring

Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2,828

Planned (sponsor's estimate)

Start

Aug 26, 2024

Primary completion

May 31, 2031

Study completion Jun 30, 2032

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with ulcerative colitis (UC) who were exposed to ozanimod during pregnancy; the second is women with UC exposed to conventional therapy during pregnancy; the third is women with UC exposed to advanced therapy during pregnancy. This study will use data from a large US healthcare claims database.

Conditions

  • Ulcerative Colitis

Interventions

  • OzanimodDrug

    Women with UC exposed to ozanimod during pregnancy

  • Conventional therapyDrug

    Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy

  • Advanced therapyDrug

    Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of major congenital malformations among infantsTime frame: Up to 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OptumInsight Life Sciences Inc

    Eden Prairie, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.